The U.S. Food and Drug Administration has granted accelerated approval for Hepcludex, the first approved treatment for chronic hepatitis delta virus infection in U.S. adults, which is putting Gilead Sciences (GILD) in focus for many healthcare investors.

Alongside the Hepcludex approval and updates around Livdelzi and Trodelvy, Gilead’s share price has risen 10.55% year to date and its 1 year total shareholder return is 25.37%, which points to firm but not runaway momentum around the stock.

If this kind of pipeline driven story interests you, it can be useful to compare Gilead with other potential healthcare opportunities using our screener for 37 healthcare AI stocks

Yet even with Hepcludex, Livdelzi and Trodelvy driving attention, some models suggest that Gilead currently trades at a near 50% intrinsic discount. This raises a key question: is the stock quietly undervalued, or is the market already accounting for potential future growth?

Most Popular Narrative: 4.7% Overvalued

According to the most followed narrative on Gilead Sciences, the fair value sits at $128.38 compared with the last close of $134.43. This points to a small valuation gap that hinges on how investors view its earnings power and pipeline depth.

Gilead is transitioning from a “single-franchise HIV company” into a multi-platform biopharma with high probability growth drivers such as lenacapavir and Trodelvy. At the same time, high upside optionality in cell therapy and immunology is coming through an M&A heavy playbook that brings near term earnings volatility but a clearer medium term growth profile.

Want to see what is baked into that $128.38 figure? The narrative leans on strong cash generation, rising margins and a future earnings multiple that is usually reserved for faster growing large caps.

Result: Fair Value of $128.38 (OVERVALUED)

However, this hinges on complex oncology execution and M&A integration. Weaker trial outcomes or slower assimilation of acquisitions could quickly challenge that fair value story.

Another View: Multiples Point To A Different Story

While the user narrative pegs fair value at $128.38 and tags Gilead as 4.7% overvalued, Simply Wall St’s own work with the P/E ratio paints a different picture. At 18.1x, the stock trades well below the peer average of 42.6x and under the fair ratio of 31x. This implies the market could be assigning a wide safety margin rather than pricing in pipeline optionality. Is that caution warranted, or is sentiment simply lagging the fundamentals?

Next Steps

With mixed signals on valuation and sentiment, consider reviewing the full picture for yourself and acting while opinions are still divided by checking the 4 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop with just one stock, you risk missing other opportunities that might fit your goals even better, so keep broadening your watchlist thoughtfully.

• Spot potential turnaround stories early by checking out 23 elite penny stocks with strong financials that already show stronger financial footing than typical low priced stocks.
• Zero in on quality at a discount by scanning companies in the 46 high quality undervalued stocks that pair solid fundamentals with appealing valuations.
• Prioritise staying power by reviewing the 62 resilient stocks with low risk scores that screens for resilience and lower risk profiles before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.